Cargando…

Erratum to: On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers

Detalles Bibliográficos
Autores principales:	Vermeeren, Annemiek, Jongen, Stefan, Murphy, Patricia, Moline, Margaret, Filippov, Gleb, Pinner, Kate, Perdomo, Carlos, Landry, Ishani, Majid, Oneeb, Van Oers, Anita C M, Van Leeuwen, Cees J, Ramaekers, Johannes G, Vuurman, Eric F P M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7355396/ https://www.ncbi.nlm.nih.gov/pubmed/32396197 http://dx.doi.org/10.1093/sleep/zsaa068

Ejemplares similares

On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers
por: Vermeeren, Annemiek, et al.
Publicado: (2018)

Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexant
por: Dayal, Satish, et al.
Publicado: (2021)

Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant
por: Landry, Ishani, et al.
Publicado: (2021)

On-the-road driving performance the morning after bedtime use of suvorexant 15 and 30 mg in healthy elderly
por: Vermeeren, Annemiek, et al.
Publicado: (2016)

Population Pharmacokinetics and Exposure‐Response Analyses for the Most Frequent Adverse Events Following Treatment With Lemborexant, an Orexin Receptor Antagonist, in Subjects With Insomnia Disorder
por: Lalovic, Bojan, et al.
Publicado: (2020)

Assessment of morning sleep propensity with lemborexant in adults with insomnia disorder in a randomized, placebo-controlled crossover study
por: Mayleben, David, et al.
Publicado: (2021)

Effect of alcohol coadministration on the pharmacodynamics, pharmacokinetics, and safety of lemborexant: A randomized, placebo-controlled crossover study
por: Landry, Ishani, et al.
Publicado: (2022)

Effects of Lemborexant on the Pharmacokinetics of Oral Contraceptives: Results From a Phase 1 Drug‐Drug Interaction Study in Healthy Females
por: Landry, Ishani, et al.
Publicado: (2021)

Abuse Potential of Lemborexant, a Dual Orexin Receptor Antagonist, Compared With Zolpidem and Suvorexant in Recreational Sedative Users
por: Landry, Ishani, et al.
Publicado: (2022)

Acute Cognitive Effects of the Dual Orexin Receptor Antagonist Lemborexant Compared With Suvorexant and Zolpidem in Recreational Sedative Users
por: Landry, Ishani, et al.
Publicado: (2022)

Alcohol calibration of tests measuring skills related to car driving
por: Jongen, Stefan, et al.
Publicado: (2014)

Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2
por: Kärppä, Mikko, et al.
Publicado: (2020)

Evaluation of the CYP3A and CYP2B6 Drug‐Drug Interaction Potential of Lemborexant
por: Landry, Ishani, et al.
Publicado: (2021)

Effect of gastric acid‐reducing agents on the pharmacokinetics and efficacy of lemborexant
por: Landry, Ishani, et al.
Publicado: (2020)

PSUN201 Efficacy and Safety of Lemborexant in Diabetic Patients With Insomnia Disorder
por: Moline, Margaret, et al.
Publicado: (2022)

Sensitivity and Validity of Psychometric Tests for Assessing Driving Impairment: Effects of Sleep Deprivation
por: Jongen, Stefan, et al.
Publicado: (2015)

Efficacy and safety of lemborexant in midlife women with insomnia disorder
por: Terauchi, Masakazu, et al.
Publicado: (2023)

P096 Subjective ratings of medication strength of lemborexant over 6 months in subjects with moderate or severe insomnia
por: Drake, C, et al.
Publicado: (2021)

The abuse potential of lemborexant, a dual orexin receptor antagonist, according to the 8 factors of the Controlled Substances Act
por: Moline, Margaret, et al.
Publicado: (2023)

P097 Incidence of abnormal dreams and nightmares with lemborexant in adults with insomnia: results from two Phase 3 studies
por: Roth, T, et al.
Publicado: (2021)

Comparing the effects of oxazepam and diazepam in actual highway driving and neurocognitive test performance: a validation study
por: Jongen, S., et al.
Publicado: (2018)

Effect of discontinuation of lemborexant following long‐term treatment of insomnia disorder: Secondary analysis of a randomized clinical trial
por: Takaesu, Yoshikazu, et al.
Publicado: (2023)

Pharmacokinetics, Pharmacodynamics, and Safety of the Dual Orexin Receptor Antagonist Lemborexant: Findings From Single‐Dose and Multiple‐Ascending‐Dose Phase 1 Studies in Healthy Adults
por: Landry, Ishani, et al.
Publicado: (2020)

Respiratory safety of lemborexant in healthy adult and elderly subjects with mild obstructive sleep apnea: A randomized, double‐blind, placebo‐controlled, crossover study
por: Cheng, Jocelyn Y., et al.
Publicado: (2020)

Efficacy and safety of lemborexant over 12 months in Asian adults with insomnia disorder
por: Dash, Amitabh, et al.
Publicado: (2022)

Physiologically‐based pharmacokinetic modeling to predict drug interactions of lemborexant with CYP3A inhibitors
por: Ueno, Takashi, et al.
Publicado: (2021)

Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial
por: Rosenberg, Russell, et al.
Publicado: (2019)

Lemborexant for insomnia
Publicado: (2021)

The effect of lemborexant for insomnia disorder
por: Suzuki, Hidenobu, et al.
Publicado: (2021)

Comparison of the antihypertensive efficacy of morning and bedtime dosing on reducing morning blood pressure surge: A protocol for systemic review and meta-analysis
por: Zhang, Peng, et al.
Publicado: (2021)

A pooled analysis of on-the-road highway driving studies in actual traffic measuring standard deviation of lateral position (i.e., “weaving”) while driving at a blood alcohol concentration of 0.5 g/L
por: Jongen, S., et al.
Publicado: (2017)

Circadian Phase Advances in Response to Weekend Morning Light in Adolescents With Short Sleep and Late Bedtimes on School Nights
por: Misiunaite, Ieva, et al.
Publicado: (2020)

On-the-road driving performance after use of the antihistamines mequitazine and l-mequitazine, alone and with alcohol
por: van der Sluiszen, N. N. J. J. M., et al.
Publicado: (2016)

Validating lane drifts as a predictive measure of drug or sleepiness induced driving impairment
por: Vinckenbosch, F. R. J., et al.
Publicado: (2020)

Pilot Study of Lemborexant for Insomnia in Cancer Patients with Delirium
por: Terada, Tatsuto, et al.
Publicado: (2022)

Bedtime-to-Morning Glucose Difference and iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of LixiLan-L
por: Zisman, Ariel, et al.
Publicado: (2018)

Evaluation of Bedtime vs. Morning Levothyroxine Intake to Control Hypothyroidism in Older Patients: A Pragmatic Crossover Randomized Clinical Trial
por: de Mello, Renato Bandeira, et al.
Publicado: (2022)

Cost-effectiveness analysis of lemborexant for treating insomnia in Japan: a model-based projection, incorporating the risk of falls, motor vehicle collisions, and workplace accidents
por: Ikeda, Shunya, et al.
Publicado: (2022)

The Effects of Transition from Bedtime to Morning Glargine Administration in Patients with Poorly Regulated Type 1 Diabetes Mellitus: Croatian Pilot Study
por: Gradiser, Marina, et al.
Publicado: (2015)

A Phase 1, Dose-Ranging Study to Assess Safety and Psychoactive Effects of a Vaporized 5-Methoxy-N, N-Dimethyltryptamine Formulation (GH001) in Healthy Volunteers
por: Reckweg, Johannes, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kpb6niv9465nu7tsgkg3o4l8h3